Stephen Ruddy has been appointed chief technical officer of Waltham, MA-based Deciphera Pharmaceuticals (NASDAQ: [[ticker:DCPH]]). Before joining Deciphera, Ruddy was vice president of pharmaceutical development at Tesaro (NASDAQ: [[ticker:TSRO]]), also based in Waltham. Last year, Deciphera raised $128 million in an IPO to finance clinical testing of its cancer drug DCC-2618 in patients who have tumors in the gastrointestinal tract.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
